Author:
Rizwan Amna,Asghar Asfandyar,Sughra Ume,Yasmin Naila
Abstract
PURPOSE:
The purpose is to study the incidence, characteristics, management, and visual outcome of endophthalmitis postintravitreal bevacizumab (Avastin®) injections.
METHODS:
Retrospective cohort study conducted at Fauji Foundation Hospital that is a tertiary care center in Rawalpindi, Pakistan. The study duration was from January 1, 2015 to March 31, 2020. A total of 2321 eyes of 1407 patients were treated with Intravitreal bevacizumab (IVB) in a minor operation theater using standard aseptic measures. We studied the incidence, clinical characteristics, treatment, and visual outcomes of endophthalmitis post-IVB.
RESULTS:
Seven eyes (0.30%) out of 2321 eyes developed post-IVB endophthalmitis during the study period. Three eyes (42.8%) were culture positive and four eyes (57.2%) were culture negative. Five eyes (71.4%) showed visual improvement and two eyes (28.6%) did not show visual improvement.
CONCLUSION:
Prompt intravitreal antibiotic along with vitreous tap in cases of postintravitreal endophthalmitis may prevent vision loss which provides a useful alternative to immediate pars plana vitrectomy that requires more expertise, equipment, and an operation theater.
Reference20 articles.
1. Role of bevacizumab in the prevention of early postoperative haemorrhage after 25-gauge microincision vitrectomy surgery;Sultan;Pak J Med Sci,2016
2. Intravitreal injections with vascular endothelial growth factor inhibitors: A practical approach;Petri;Ophthalmol Ther,2020
3. Complications of different intravitreal anti VEGF injections at multiple centers observing different protocols;Khaqan;Pak J Ophthalmol,2019
4. Incidence of endophthalmitis after intravitreal injections: Risk factors, microbiology profile, and clinical outcomes;Mishra;Ocul Immunol Inflam,2018
5. Causative Pathogens in Endophthalmitis after Intravitreal Injection of Anti-vascular Endothelial Growth Factor Agents;Labardini;Rambam Maimonides Med J,2018